Abstract
In public health, the issue of pharmaceutical pricing is a perennial problem. Recent high-profile examples, such as the September 2015 debacle involving Martin Shkreli and Turing Pharmaceuticals, are indicative of larger, systemic difficulties that plague the pharmaceutical industry in regards to drug pricing and the impact it yields on their reputation in the eyes of the public. For public health ethics, the issue of pharmaceutical pricing is rather crucial. Simply, individuals within a population require pharmaceuticals for disease prevention and management. In order to be effective, these pharmaceuticals must be accessibly priced. This analysis will explore the notion of corporate social responsibility in regards to pharmaceutical pricing with an aim of restoring a positive reputation upon the pharmaceutical industry in the public eye. The analysis will utilize the 2005 United Nations Educational, Scientific, and Cultural Organization’s Universal Declaration on Bioethics and Human Rights (UDBHR) to establish implications regarding the societal responsibilities of pharmaceutical companies in a global context. To accomplish this, Article 14 of the UDBHR—social responsibility and health—will be articulated in order to advocate a viewpoint of socially responsible capitalism in which pharmaceutical companies continue as profit-making ventures, yet establish moral concern for the welfare of all their stakeholders, including the healthcare consumer.
Similar content being viewed by others
References
Access to Medicine Index. 2014. The Access to Medicine Index 2014. Accessed April 14, 2016. http://www.accesstomedicineindex.org/sites/2015.atmindex.org/files/2014_accesstomedicineindex_pricing_0.pdf.
Argenti, Paul A., and Bob Druckenmiller. 2004. Reputation and the corporate brand. Corporate Reputation Review 6(4): 368–374. doi:10.2139/ssrn.387860.
Baum, Stephanie. 2013. Survey finds lack of transparency drags down pharma reputation among patient groups. Accessed September 7, 2016. http://medcitynews.com/2013/01/lack-of-transparency-drags-down-pharma-reputation-among-patient-groups-survey/?rf=1.
Bluestone, Ken, Annie Heaton, and Christopher Lewis. 2002. Beyond philanthropy: The pharmaceutical industry, corporate social responsibility and the developing world. Ed. Bonita Glanville Morris. London: Oxfam.
Brigham, Alexander F., and Stefan Linssen. 2010. Your Brand Reputational Value Is Irreplaceable. Protect It! Forbes. Accessed April 14, 2016. http://www.forbes.com/2010/02/01/brand-reputation-value-leadership-managing-ethisphere.html.
Çaliskan, Arzu Özsözgün. 2015. How UN global compact can contribute accountability and sustainability. In The UN global compact: Fair competition and environmental and labour justice in international markets, ed. Maria-Alejandra Gonzalez-Perez, and Liam Leonard, 17–36. Bingley: Emerald.
Chong, Mark. 2012. Importance of Corporate Reputation. The Business Times. Accessed April 14, 2016. http://ink.library.smu.edu.sg/lkcsb_research/3277/.
Cohn, Jonathan. 2016. Drugs you don’t need for disorders you don’t have: Inside the pharmaceutical industry’s campaign to put us all to sleep. The Huffington Post. Accessed April 14, 2016. http://highline.huffingtonpost.com/articles/en/sleep-advertising/.
Daniels, Norman. 2001. Social responsibility and global pharmaceutical companies. Developing World Bioethics 1(1): 38–41.
DiJulio, Bianca, Jamie Firth, and Mollyann Brodio Follow. 2015. Kaiser health tracking poll: August 2015.” The Henry J. Kaiser Family Foundation. Accessed April 14, 2016. http://kff.org/health-costs/poll-finding/kaiser-health-tracking-poll-august-2015/.
Droppert, Hayley, and Sara Bennett. 2015. Corporate social responsibility in global health: An exploratory study of multinational pharmaceutical firms. Globalization and Health. doi:10.1186/s12992-015-0100-5.
Egan, Matt. 2016. How EpiPen came to symbolize corporate greed. CNN Money. Accessed September 7, 2016. http://money.cnn.com/2016/08/29/investing/epipen-price-rise-history/index.html.
Finegold, David L., Cécile M. Bensimon, Abdallah S. Daar, Margaret L. Eaton, Béatrice Godard, Bartha Maria Knoppers, Jocelyn E. Mackie, and Peter A. Singer. 2005. Bioindustry ethics. Burlington, MA: Elsevier.
First, Harry. 2015. Unfair Drug Prices and Section 5. NYU law and economics research paper no. 16-03. CPI Antitrust Chronicle November 2015 (2). Accessed April 14, 2016. http://papers.ssrn.com/sol3/papers.cfm?abstract_id=2699843.
Fisher, William W., and Cyril P. Rigamonti. 2005. The South Africa AIDS controversy: A case study in patent law and policy. Harvard Law School. Accessed April 14, 2016. http://cyber.law.harvard.edu/people/tfisher/South%20Africa.pdf.
Friedman, Milton. 1970. The social responsibility of business is to increase its profits. The New York Times Magazine. Accessed April 14, 2016. http://www.mvopat.people.ysu.edu/courses/business_ethics/business_ethics_readings/Social_Responsibility_Friedman.pdf.
Global Compact Self-Assessment Tool. Accessed September 7, 2016. http://www.globalcompactselfassessment.org.
Goodfellow, Maya. 2015. Five times that big pharmaceutical companies have screwed over sick people more than Martin Shkreli. The Independent. Accessed April 14, 2016. http://www.independent.co.uk/voices/comment/five-times-that-big-pharmaceutical-companies-have-screwed-over-sick-people-more-than-martin-shkreli-10515435.html.
Harris Interactive. 2013. The Harris Poll 2013 RQ summary report. Accessed September 7, 2016. http://www.rankingthebrands.com/PDF/The%20Reputations%20of%20the%20Most%20Visible%20Companies%202013,%20Harris%20Interactive.pdf.
Hesselbein, Frances. 2010. How did Peter Drucker see corporate responsibility? Harvard Business Review. Accessed April 14, 2016. https://hbr.org/2010/06/how-did-peter-drucker-see-corp/.
Hirschler, Ben. 2015. Exclusive—Transatlantic divide: How U.S. pays three times more for drugs. Reuters. Accessed April 14, 2016. http://www.reuters.com/article/us-pharmaceuticals-usa-comparison-idUSKCN0S61KU20151012.
Hogerzeil, Hans V. 2013. Big Pharma and Social Responsibility—The Access to Medicine Index. New England Journal of Medicine 369(10): 896–899. doi:10.1056/NEJMp1303723.
Hwang, Jung Joo. 2012. Is Merck’s corporate social responsibility good for the global health? Accessed April 14, 2016. https://gps.ucsd.edu/_files/faculty/gourevitch/gourevitch_cs_hwang_jungjoo.pdf.
Kessel, Mark. 2014. Restoring the pharmaceutical industry’s reputation. Nature 32(10): 983–990. doi:10.1038/nbt.3036.
Lawrence, Joanne T. 2013. Responsible business: A brief perspective. In Globally responsible leadership: Managing according to the UN global compact, ed. Joanne T. Lawrence, and Paul W. Beamish, 3–19. Thousand Oaks, CA: SAGE Publication.
Leisinger, Klaus M. 2005. The corporate social responsibility of the pharmaceutical industry: Idealism without illusion and realism without resignation. Business Ethics Quarterly 15(4): 577–594.
Lewis, Neil A. 1999. U.S. Industry to drop AIDS drug lawsuit against South Africa. The New York Times. Accessed April 14, 2016. http://www.nytimes.com/1999/09/10/world/us-industry-to-drop-aids-drug-lawsuit-against-south-africa.html.
Macklin, Ruth. 2004. Double standards in medical research in developing countries. Cambridge: Cambridge University Press.
Martínez-Palomo, Adolfo. 2009. Article 14: Social responsibility and health. In The UNESCO universal declaration on bioethics and human rights: Background, principles and application, ed. Henk ten Have, and Michele S. Jean. Paris: UNESCO.
McNeil, Donald G. 2001. Oxfam joins campaign to cut drug prices for poor nations. The New York Times. Accessed April 14, 2016. http://www.nytimes.com/2001/02/13/world/oxfam-joins-campaign-to-cut-drug-prices-for-poor-nations.html.
Médecins Sans Frontières. 2014. Untangling the antiretroviral price reductions, 17th ed. Accessed April 14, 2016. https://www.msfaccess.org/sites/default/files/MSF_UTW_17th_Edition_4_b.pdf.
Mill, John Stuart. 2001. Utilitarianism. Second edition. Ed. George Sher. Indianapolis: Hackett Publishing Company.
Mohammed, Rafi. 2015. It’s time to rein in exorbitant pharmaceutical prices. Harvard Business Review. Accessed April 14, 2016. https://hbr.org/2015/09/its-time-to-rein-in-exorbitant-pharmaceutical-prices.
Mullin, Emily. 2015. Turing pharma says Daraprim availability will be unaffected by Shkreli Arrest. Forbes. Accessed April 14, 2016. http://www.forbes.com/sites/emilymullin/2015/12/21/turing-pharma-says-daraprim-availability-will-be-unaffected-by-shkreli-arrest/#1dccb8c02e82.
OECD. 2008. Pharmaceutical pricing policies in a global market. OECD, Accessed April 14, 2016. http://apps.who.int/medicinedocs/documents/s19834en/s19834en.pdf.
Parker, Jane. 2007. The reputation, image and influence of the pharmaceutical industry: Regaining credibility. Journal of Medical Marketing 7(4): 309–313. doi:10.1057/palgrave.jmm.5050098.
Pfeffer, Jeffrey. 2009. Shareholders first? Not so fast…. Harvard Business Review. Accessed April 14, 2016. https://hbr.org/2009/07/shareholders-first-not-so-fast.
Pollack, Andrew. 2015. Drug prices soar, prompting calls for justification. The New York Times. Accessed April 14, 2016. http://www.nytimes.com/2015/07/23/business/drug-companies-pushed-from-far-and-wide-to-explain-high-prices.html?_r=0.
Read, Ian C. 2014. You gain respect in drops, but can lose it in gallons. Accessed April 14, 2016. https://www.linkedin.com/pulse/20140219125245-322581966-you-gain-respect-in-drops-but-can-lose-it-in-gallons.
Reputation Institute. 2016. Pharmaceutical industry reputation in recovery as global pharma RepTrak® finds public perceptions improving. Accessed September 7, 2016. https://www.reputationinstitute.com/CMSPages/GetAzureFile.aspx?path=~%5Cmedia%5Cmedia%5Cmedia%5Cpress-release-for-2016-pharma-reptrak_final_052516.pdf&hash=2dc09d5d2f11f53cc1da33218e407ef49acc5024a5ed72028ebb4cf36157e9d0.
Resnik, David B. 2001. Developing drugs for the developing world: An economic, legal, moral, and political dilemma. Developing World Bioethics 1(1): 11–32.
Resnik, David B. 2014. Scientific misconduct and research integrity. In Handbook of global bioethics, ed. Henk ten Have, and Bert Gordijn, 799–810. Dordrecht: Springer.
Ruggie, John Gerard. 2013. Just business: Multinational corporations and human rights. New York: Norton.
Sandel, Michael J. 2009. Justice: What’s the right thing to do?. New York: Farrar, Strauss, and Giroux.
Semplici, Stefano. 2014. Social responsibility and health. In Handbook of global bioethics, ed. Henk ten Have, and Bert Gordijn, 187–201. Dordrecht: Springer.
Spinello, Richard A. 1992. Ethics, pricing and the pharmaceutical industry. Journal of Business Ethics 11(8): 617–626. doi:10.1007/BF00872273.
Stossel, Thomas Peter. 2016. Prescription drug price controls pose lethal problems. American Enterprise Institute. Accessed April 14, 2016. http://www.aei.org/publication/prescription-drug-price-controls-pose-lethal-problems/?utm_source=paramount&utm_medium=email&utm_content=AEITODAY&utm_campaign=032816?utm_source=twitter&utm_medium=social&utm_campaign=StosselDrugpricecontrols.
ten Have, Henk. 2016. Global bioethics: An introduction. Abingdon, Oxon: Routledge.
The Economist. 2004. Two-faced capitalism. The Economist. Accessed April 14, 2016. http://www.economist.com/node/2369912.
The Economist. 2015. Pharmaceutical pricing: Crippling. The Economist. Accessed April 14, 2016. http://www.economist.com/blogs/democracyinamerica/2015/06/pharmaceutical-pricing.
The Economist. 2016. For my next trick…. The Economist. March 26, 85–86.
The Wharton School. 2011. Profits and social responsibility: Chastened drug makers step up efforts to bring affordable medicines to poor countries. The Wharton School, University of Pennsylvania. Accessed April 14, 2016. http://knowledge.wharton.upenn.edu/article/profits-and-social-responsibility-chastened-drug-makers-step-up-efforts-to-bring-affordable-medicines-to-poor-countries/.
UNESCO. 2010. Report of the international bioethics committee of UNESCO (IBC): On social responsibility and health. Paris: UNESCO.
UNESCO Universal Declaration on Bioethics and Human Rights. October 19, 2005.
United Nations. 2007. CSR and developing countries. Sustainable Development Innovation Briefs. Accessed August 15, 2016. https://sustainabledevelopment.un.org/content/documents/no1.pdf.
United Nations Global Compact. Our Strategy. Accessed April 14, 2016. https://www.unglobalcompact.org/what-is-gc/strategy.
Vachani, Sushil, and N.Craig Smith. 2004. Socially responsible pricing: Lessons from the pricing of AIDS drugs in developing countries. California Management Review 47(1): 117–144. doi:10.2307/41166289.
Yadav, Prashat. 2010. Differential pricing for pharmaceuticals: Review of current knowledge, new findings and ideas for action. Accessed April 14, 2016. http://apps.who.int/medicinedocs/documents/s18390en/s18390en.pdf.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hurst, D.J. Restoring a reputation: invoking the UNESCO Universal Declaration on Bioethics and Human Rights to bear on pharmaceutical pricing. Med Health Care and Philos 20, 105–117 (2017). https://doi.org/10.1007/s11019-016-9743-0
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11019-016-9743-0